Ensure Successful Development of Scientific Communication Platforms

STUDY OVERVIEW
BENCHMARK CLASS
SPECIAL OFFER

Non-members: Click here to review a complimentary excerpt from “Scientific Communication Platform Excellence: Development, Format and Location”

STUDY OVERVIEW

As part of their medical and scientific communications strategy, many pharmaceutical and medical device companies have established scientific communication platforms (SCPs) to align communications and value messaging across key functional areas.

However, many organizations still lack clear processes to ensure successful development of scientific communication platforms. Also, SCP format and content have advanced considerably to keep pace with the dynamic healthcare environment.

Best Practices, LLC undertook this benchmarking research to help medical communications/publications leaders with SCP development, format, location, and timing of updates. The study delivers current practices around SCPs and covers what functions are involved in SCP development and how frequently are SCPs developed.

KEY TOPICS

Scientific Communication Platform Development
Format and Location of Scientific Communication Platforms
Timing of Scientific Communication Platform Updates

KEY METRICS

What function(s) leads the development of scientific communication platforms (SCP)?
What approach is undertaken by benchmark partners to develop the SCP?
What function(s) or group(s) provide input into the development of SCP?
Which group is involved in the approval process for scientific communication platforms?
What point in the product lifecycle is ideal to develop the initial SCP?
How frequently do benchmark partners develop a SCP?
What SCP format is utilized by benchmark organizations?
Where is SCP housed within benchmark companies?
What information is required in the scientific communication platform for it to be most useful?
When do benchmark companies update their scientific communication platforms?

SAMPLE KEY FINDINGS

Timing for Initial SCP Development: There is no clear standard for when organizations start the SCP development process across company segments. More than a third of participants initiate SCP development during Phase 2 studies.

METHODOLOGY

Best Practices, LLC engaged 21 Medical leaders from 21 pharma companies in this research through a benchmarking survey. Data in this study is further segmented by mid-small vs. large companies to provide in-depth insights.

Industries Profiled:
Biopharmaceutical; Pharmaceutical; Biotech; Health Care; Consumer Products; Communications; Laboratories

Companies Profiled:
Alkermes; Astellas; AstraZeneca; BELLUS Health; Boehringer Ingelheim; GlaxoSmithKline ; Gossamer Bio; Incyte; Ipsen; Merck; Nobel Biocare; Novartis; Novo Nordisk; OPEN Health; Oxford PharmaGenesis; Pfizer; Pierre Fabre; Sandoz; Spark Therapeutics; Torrent Pharmaceuticals Ltd.; UniQure

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.

Scientific Communication Platform Excellence: Development, Format and Location

ID: 5741

Features:

Pages/Slides: 34

Published: 2022

Delivery Format: Online PDF Document

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
62BEC380C0152DC6B002588F6003EC8E3
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-scientific-communication-platform-excellence-development-format-location?opendocument
18
19opendocument
2018.97.14.91
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB